Section Arrow
IMUX.NASDAQ
- Immunic
(Financial Status)
Quotes are at least 15-min delayed:2025/07/21 06:53 EDT
Pre Market
Last
 0.9652
+0.0012 (+0.12%)
Bid
0.964
Ask
0.9998
High 0.9899 
Low 0.9642 
Volume 12140 
Regular Hours
Last
 0.964
+0.034 (+3.66%)
Day High 
Prev. Close
0.93 
1-M High
0.979 
Volume 
1.82M 
Bid
0.964
Ask
0.9998
Day Low
0.9407 
Open
0.98 
1-M Low
0.67705 
Market Cap 
89.11M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.83 
20-SMA 0.77 
50-SMA 0.84 
52-W High 2.11 
52-W Low 0.561001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.95/-0.47
Enterprise Value
89.37M
Balance Sheet
Book Value Per Share
-0.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.975 -0.305 -13.38%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.1 -0.975 -6.93%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.26 +0.42 +7.19%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.07 +0.15 +2.53%
Quotes are at least 15-min delayed:2025/07/21 06:53 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.